Navellier & Associates Inc Purchases Shares of 15,901 Supernus Pharmaceuticals Inc (SUPN)

Share on StockTwits

Navellier & Associates Inc purchased a new stake in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) during the second quarter, Holdings Channel reports. The fund purchased 15,901 shares of the specialty pharmaceutical company’s stock, valued at approximately $952,000.

Other institutional investors also recently added to or reduced their stakes in the company. Everence Capital Management Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $205,000. Cim LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $207,000. Diversified Trust Co purchased a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at approximately $211,000. Wesbanco Bank Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at approximately $229,000. Finally, Mount Yale Investment Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at approximately $238,000. 98.01% of the stock is currently owned by institutional investors and hedge funds.

Shares of Supernus Pharmaceuticals opened at $46.15 on Friday, Marketbeat.com reports. The company has a quick ratio of 4.74, a current ratio of 2.74 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $2.49 billion, a P/E ratio of 26.87 and a beta of 0.97. Supernus Pharmaceuticals Inc has a fifty-two week low of $33.30 and a fifty-two week high of $61.25.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.14. The firm had revenue of $99.54 million during the quarter, compared to analysts’ expectations of $101.01 million. Supernus Pharmaceuticals had a net margin of 24.17% and a return on equity of 30.57%. research analysts predict that Supernus Pharmaceuticals Inc will post 1.91 EPS for the current year.

A number of equities research analysts have recently issued reports on the stock. BidaskClub raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 22nd. ValuEngine raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 12th. Piper Jaffray Companies set a $47.00 price target on shares of Supernus Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, July 2nd. Stifel Nicolaus boosted their price target on shares of Supernus Pharmaceuticals from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, May 25th. Finally, Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. Supernus Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $54.09.

In related news, CFO Gregory S. Patrick sold 35,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $56.63, for a total value of $1,982,050.00. Following the completion of the transaction, the chief financial officer now owns 75,975 shares in the company, valued at $4,302,464.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Stefan K.F. Schwabe sold 60,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Monday, June 18th. The shares were sold at an average price of $54.39, for a total transaction of $3,263,400.00. Following the completion of the transaction, the vice president now owns 21,967 shares of the company’s stock, valued at approximately $1,194,785.13. The disclosure for this sale can be found here. Insiders sold 117,868 shares of company stock valued at $6,600,620 in the last 90 days. Company insiders own 6.20% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Featured Story: Diversification

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply